Tildrakizumab
- Generic Name
- Tildrakizumab
- Brand Names
- Ilumya, Ilumetri
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1326244-10-3
- Unique Ingredient Identifier
- DEW6X41BEK
- Background
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
...
- Indication
Moderate-severe plaque psoriasis , .
- Associated Conditions
- Moderate to Severe Plaque Psoriasis
- Associated Therapies
- -
Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 51
- Registration Number
- NCT04112810
- Locations
- 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 130
- Registration Number
- NCT03997786
- Locations
- 🇺🇸
Site 2, Thousand Oaks, California, United States
🇺🇸Site 1, Fountain Valley, California, United States
🇺🇸Site 20, Miami, Florida, United States
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 99
- Registration Number
- NCT03897075
- Locations
- 🇺🇸
California Dermatology & CRI (Site 18), Encinitas, California, United States
🇺🇸First OC Dermatology (Site 07), Fountain Valley, California, United States
🇺🇸Dermatology Research Associates (Site 09), Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.